China’s WuXi AppTec acquires US clinical service company Pharmapace

Photo: WuXi AppTec.

WuXi AppTec, a global pharmaceutical and medical device company with operations in China, has announced the acquisition of Pharmapace Inc, a US-based clinical research services company.

Founded in 2013 in California, Pharmapace provides biometric services for all stages of clinical trials such as clinical and statistical programming, data management and biostatistics.

Post acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical, the clinical contract research organisation arm of WuXi AppTec.

The acquisition will help WuXi expand its biometrics capabilities in the United States and Europe.

“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services globally,” said WuXi AppTec co-CEO Edward Hu.

Pharmapace will continue its focus on growing its core biometric competencies and integrate with WuXi Clinical’s other clinical development services.

With the two organisations teaming up, WuXi Clinical claims it has over 850 employees in China and the US and can provide a full range of clinical development services to its customers.

China is a leading clinical trial market in Asia and with the recent regulatory changes made by the China Food and Drug Administration, clinical trial institutions and investigators are expected to get more support for clinical trial developments.

Also Read:

China’s WuXi AppTec co-leads $85m round for Bill Gates-backed Schrödinger

China’s WuXi AppTec ends flat in Hong Kong trading debut

Chinese biotech firm WuXi AppTec said to raise $1b in HK share sale

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.